Integrating gut microbiome and neuroplasticity genomics in alcohol use disorder therapy
Koutromanos I, Legaki E, Dovrolis N, Vassilopoulos E, Stem A, Vasiliou V, Tzavellas E, Gazouli M. Integrating gut microbiome and neuroplasticity genomics in alcohol use disorder therapy. Human Genomics 2025, 19: 78. PMID: 40646629, PMCID: PMC12255058, DOI: 10.1186/s40246-025-00793-y.Peer-Reviewed Original ResearchConceptsGut microbiotaShort-chain fatty acid (SCFA)-producing bacteriaMetabolic pathwaysStress-related metabolic pathwaysHost-microbiota interactionsMicrobial metabolic pathwaysMulti-omics approachGut barrier integrityGene expression changesGene expression profilesNeuroplasticity-related genesRRNA sequencingGut microbiomeFamily genesGenomic signaturesMicrobiome compositionMicrobial compositionAUD patientsMicrobial dysbiosisTreatment responseFunctional pathwaysGene expressionMicrobiomeGenesExpression changes4.09 Aldehyde Dehydrogenases
Vasiliou V, Lisgara A, Krupenko S, Krupenko N, Alayyoub M, Petersen D, Thompson D. 4.09 Aldehyde Dehydrogenases. 2025, 183-210. DOI: 10.1016/b978-0-323-95488-4.00287-4.Peer-Reviewed Original ResearchAldehyde dehydrogenaseTransgenic knockout mouse modelLate-onset Alzheimer's diseaseAldehyde dehydrogenase superfamilyAldehyde dehydrogenase geneNAD(P)+-dependent enzymesType II hyperprolinemiaHuman genomeDehydrogenase geneKnockout mouse modelPoor cancer prognosisExogenous aldehydesMolecular basisSpastic paraplegiaPhysiological processesAlzheimer's diseaseDe Barsy syndromeClinical phenotypeSjogren-Larsson syndromeGenesCancer stem cellsDehydrogenaseEnzyme inactivationEnzymeBarsy syndrome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply